Literature DB >> 15455745

A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes.

Søren Jepsen1, Bernd Heinz, Karin Jepsen, Mehrdad Arjomand, Thomas Hoffmann, Steffen Richter, Elmar Reich, Anton Sculean, José R Gonzales, Rolf H Bödeker, Jörg Meyle.   

Abstract

BACKGROUND: The objective of this multicenter, randomized trial was to compare enamel matrix derivative (EMD; test) with barrier membranes (control) for the treatment of mandibular buccal Class II furcation defects.
METHODS: Forty-five patients with 90 comparable defects on contralateral molars were included. Defects were randomly assigned to EMD or bioabsorbable barrier membrane; the contralateral defect received the alternative treatment. Assessments at baseline and 8 and 14 months included gingival margin levels, probing depths, bleeding on probing, vertical attachment levels, and vertical bone sounding from a stent at five buccal sites/ tooth. Defect dimensions were recorded at surgery and during reentry at 14 months. Change of open horizontal furcation depth was the primary outcome variable. Adverse reactions and patient perceptions were also noted.
RESULTS: Both treatment modalities led to significant clinical improvements. The median reduction of open horizontal furcation depth was 2.8 mm with the corresponding interquartile interval (1.5 mm, 3.5 mm) at test sites compared with 1.8 mm (1.0 mm, 2.8 mm) at control sites. The Hodges-Lehmann estimator of the advantage (reduction test versus control) was 0.75 mm (95% confidence interval [CI]: 0.125 mm, 1.375 mm, P = 0.033, Wilcoxon). The frequency of complete furcation closure was 8/45 (test) and 3/45 (control); partial closure, 27/45 in both groups; no change, 9/45 and 11/45, respectively; and deterioration, 1/45 and 4/45, respectively. The frequency of no pain or no swelling at 1 week post-surgery was 62% and 44%, respectively, at the test sites and 12% and 6% at the control sites.
CONCLUSION: There was a significantly greater reduction in horizontal furcation depth and a comparatively lower incidence of postoperative pain/swelling following enamel matrix derivative compared to membrane therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455745     DOI: 10.1902/jop.2004.75.8.1150

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  20 in total

1.  Wound healing following regenerative procedures in furcation degree III defects: histomorphometric outcomes.

Authors:  Nikolaos D Gkranias; Filippo Graziani; Anton Sculean; Nikolaos Donos
Journal:  Clin Oral Investig       Date:  2010-10-22       Impact factor: 3.573

2.  Efficacy of open flap debridement with and without enamel matrix derivatives in the treatment of mandibular degree II furcation involvement.

Authors:  Mohammad Taghi Chitsazi; Ramin Mostofi Zadeh Farahani; Mohammadreza Pourabbas; Nasim Bahaeddin
Journal:  Clin Oral Investig       Date:  2007-07-11       Impact factor: 3.573

Review 3.  Interfaces between orthodontic and periodontal treatment: their current status.

Authors:  Christoph Reichert; Martin Hagner; Søren Jepsen; Andreas Jäger
Journal:  J Orofac Orthop       Date:  2011-07       Impact factor: 1.938

4.  Anti-inflammatory effects of EMD in the presence of biomechanical loading and interleukin-1β in vitro.

Authors:  Marjan Nokhbehsaim; Birgit Deschner; Jochen Winter; Christoph Bourauel; Andreas Jäger; Søren Jepsen; James Deschner
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

5.  Enamel matrix protein derivative and/or synthetic bone substitute for the treatment of mandibular class II buccal furcation defects. A 12-month randomized clinical trial.

Authors:  Lucas Araujo Queiroz; Mauro Pedrine Santamaria; Marcio Z Casati; Karina Silverio Ruiz; Francisco Nociti; Antonio Wilson Sallum; Enilson A Sallum
Journal:  Clin Oral Investig       Date:  2015-11-10       Impact factor: 3.573

6.  Premature osteoblast clustering by enamel matrix proteins induces osteoblast differentiation through up-regulation of connexin 43 and N-cadherin.

Authors:  Richard J Miron; Erik Hedbom; Sabrina Ruggiero; Dieter D Bosshardt; Yufeng Zhang; Corinna Mauth; Anja C Gemperli; Tateyuki Iizuka; Daniel Buser; Anton Sculean
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

7.  Clinical outcomes after treatment of periodontal intrabony defects with nanocrystalline hydroxyapatite (Ostim) or enamel matrix derivatives (Emdogain): a randomized controlled clinical trial.

Authors:  Elyan Al Machot; Thomas Hoffmann; Katrin Lorenz; Ihssan Khalili; Barbara Noack
Journal:  Biomed Res Int       Date:  2014-02-09       Impact factor: 3.411

8.  Enamel matrix protein derivatives: role in periodontal regeneration.

Authors:  Vandana J Rathva
Journal:  Clin Cosmet Investig Dent       Date:  2011-12-01

9.  Clinical Comparison of Autogenous Bone Graft with and without Plasma Rich in Growth Factors in the Treatment of Grade II Furcation Involvement of Mandibular Molars.

Authors:  Ardeshir Lafzi; Adileh Shirmohammadi; Masoumeh Faramarzi; Sahar Jabali; Arman Shayan
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2013-02-21

Review 10.  Biologic Agents for Periodontal Regeneration and Implant Site Development.

Authors:  Fernando Suárez-López Del Amo; Alberto Monje; Miguel Padial-Molina; ZhiHui Tang; Hom-Lay Wang
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.